Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study

ABSTRACT Background: There are insufficient predictive markers for renal cell carcinoma (RCC). Methods: A total of 308 metastatic RCC patients were analyzed retrospectively. Results: The increased hemoglobin (Hb) group had significantly higher progression-free survival and overall survival (OS) compared with the decreased Hb group at 11.5 versus 6.35 months (p < .001) and 21.0 versus 11.36 months (p < .001) respectively. The 1- and 3-year OS rates were higher in the Hb increased group, i.e., 84% versus 64% and 52% versus 35% respectively. Conclusions: The present study showed that increased Hb levels after tyrosine kinase inhibitor therapy could be a predictive marker of RCC.

[1]  V. Margulis,et al.  Cytoreductive nephrectomy for metastatic renal cell carcinoma. , 2016, Clinical advances in hematology & oncology : H&O.

[2]  Yongkun Sun,et al.  A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal cell carcinoma , 2016, Asia-Pacific journal of clinical oncology.

[3]  S. Sleijfer,et al.  Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment. , 2016, European journal of cancer.

[4]  M. Kaag,et al.  Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review. , 2015, Clinical genitourinary cancer.

[5]  W. Curran,et al.  Bevacizumab‐induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab , 2015, Cancer.

[6]  T. Choueiri,et al.  The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. , 2015, The Lancet. Oncology.

[7]  R. Motzer,et al.  Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Valachis,et al.  Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-Analysis. , 2014, Clinical genitourinary cancer.

[9]  A. Ravaud,et al.  Clinical biomarkers of response in advanced renal cell carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  T. Funakoshi,et al.  Risk of hypothyroidism in patients with cancer treated with sunitinib: A systematic review and meta-analysis , 2013, Acta oncologica.

[11]  Lauren McCann,et al.  A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. , 2013, European journal of cancer.

[12]  J. Reeves,et al.  Randomized, Open-Label, Phase III Trial Of Pazopanib Versus Sunitinib In First-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma (MRCC): Results of the Comparz Trial , 2012 .

[13]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[14]  R. Figlin,et al.  Response: Re: Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib , 2011 .

[15]  Jeffrey W. Clark,et al.  Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value , 2010, Clinical Cancer Research.

[16]  Shenhong Wu,et al.  Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials , 2010, Acta oncologica.

[17]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Autorino,et al.  Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Hans-Peter Lipp,et al.  Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. , 2009, Current drug metabolism.

[20]  S. Richard,et al.  Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Alexandrescu,et al.  Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Ravaud,et al.  Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. , 2007, The Journal of urology.

[23]  J. Christensen,et al.  Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy , 2007, Proceedings of the National Academy of Sciences.

[24]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[25]  Kevin Wei,et al.  VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis , 2006, Nature Medicine.

[26]  T. Mekhail,et al.  Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Schwartz,et al.  Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Figlin,et al.  Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. , 2003, The Journal of urology.

[29]  Steve Horvath,et al.  Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  Kazuki Kobayashi,et al.  VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. , 2002, Journal of the National Cancer Institute.

[31]  W. Chow,et al.  Global increases in kidney cancer incidence, 1973–1992 , 2002, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[32]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[33]  J. Filep.  Endogenous endothelin modulates blood pressure, plasma volume, and albumin escape after systemic nitric oxide blockade. , 1997, Hypertension.

[34]  R. Figlin,et al.  Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma? , 2016, European journal of cancer.

[35]  H. van Cruijsen,et al.  Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions. , 2009, Frontiers in bioscience.

[36]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Bassi,et al.  Prognostic factors in renal cell carcinoma. , 1988, European urology.